CD4+ T-cell receptor recognizing influenza peptide–MHC class II complex (TCR (Influenza-specific))

CD4+ T-cell receptors (TCRs) that recognize influenza peptide–MHC class II complexes are pivotal mediators of the adaptive immune response against influenza viruses. These heterodimeric receptors, consisting of alpha and beta chains, specifically identify viral peptides—most notably from hemagglutinin (HA), nucleoprotein (NP), and matrix protein (M1)—presented by Major Histocompatibility Complex (MHC) class II molecules (such as HLA-DR1 or HLA-DR4) on antigen-presenting cells (1.2.1, 1.3.1). This recognition event triggers CD4+ T-cell activation, leading to the secretion of pro-inflammatory cytokines like IFN-gamma and IL-2, and providing essential help to B cells for high-affinity antibody production (1.1.1, 1.4.3). In clinical practice, these TCRs are the primary targets of influenza vaccines, which seek to expand the repertoire of virus-specific T cells to provide long-lasting and cross-protective immunity (1.3.4, 1.4.5). Furthermore, they are being explored in the development of universal influenza vaccines and adoptive T-cell therapies (TCR-T) to combat highly mutable or pandemic strains (1.3.1). Safety considerations include the risk of cytokine release syndrome and potential cross-reactivity with self-antigens, which could trigger autoimmune responses (1.2.3).

Other names

Influenza-specific T-cell receptorMHC-II restricted TCRHA-specific TCRNP-specific TCRCD4+ TCR

Recognition of influenza-derived peptides presented by MHC class II molecules, leading to T-cell activation and orchestration of the adaptive immune response.